Arizona is currently home to 1677 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Phoenix, Tucson, Scottsdale and Mesa. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
CtDNA Based MRD Testing for NAC Monitoring in TNBC
Recruiting
A prospective, multicenter, observational study to evaluate the correlation of Molecular Residual Disease (MRD) detection using circulating tumor DNA guided test to pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in stage I-III triple negative breast cancer (TNBC). Results from this study aim to improve MRD detection and disease outcomes for future patients.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/03/2025
Locations: Arizona Oncology, Tucson, Arizona
Conditions: TNBC - Triple-Negative Breast Cancer, Minimal Residual Disease
ORB-021 In Patients With Advanced Solid Tumors
Recruiting
The goal of this clinical research study is to determine if an investigational new drug, named ORB-021, developed by Orionis Biosciences is safe and can be tolerated in people diagnosed with an advanced solid tumor. The study also aims to find the biologically optimal dose of the study medicine by assessing the safety and potential activity in the treatment of solid tumors. There are three phases to this study: screening, treatment and end of treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/02/2025
Locations: Honor Health Clinical Research, Scottsdale, Arizona
Conditions: Advanced Solid Tumors Cancer
Comparing Perioperative Education Modalities for ACL Reconstruction on Patient Satisfaction, Self-Efficacy, and Surgical Outcomes
Recruiting
The purpose of this research is to find out whether the way information about surgery is presented to patients affects patient satisfaction, knowledge retention, and surgical outcomes such as anxiety
Gender:
ALL
Ages:
Between 15 years and 65 years
Trial Updated:
01/02/2025
Locations: Mayo Clinic Arizona, Phoenix, Arizona
Conditions: ACL Injury, Anterior Cruciate Ligament Injuries
Stereotactic Biopsy Split-Course Radiation Therapy in Diffuse Midline Glioma, SPORT-DMG Study
Recruiting
This phase II trial studies the clinical outcomes of hypofractionated radiation therapy in patients with diffuse midline gliomas. This study aims to change the way radiation is delivered, from giving 6 weeks of radiation all at once to giving 2 weeks of radiation. This may determine if there is a difference in the outcome of the treatment, and most importantly, the patients' quality of life.
Gender:
ALL
Ages:
1 year and above
Trial Updated:
12/31/2024
Locations: Mayo Clinic Hospital in Arizona, Phoenix, Arizona
Conditions: Diffuse Midline Glioma, H3 K27M-Mutant
Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC
Recruiting
Open-label, Phase II, randomized, controlled study evaluating the efficacy and safety of danvatirsen in combination with pembrolizumab compared with pembrolizumab alone as first-line treatment of patients with recurrent/metastatic (R/M) HNSCC. Two-thirds of patients will be randomized to receive danvatirsen and pembrolizumab and one-third will be randomized to receive pembrolizumab alone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/27/2024
Locations: The University of Arizona Cancer Center, Tucson, Arizona
Conditions: HNSCC
Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes
Recruiting
This research will help us to learn if the medicine called metformin reduces the risk of death, heart attacks, and/or strokes in Veterans who have pre-diabetes and heart or blood vessel problems.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/27/2024
Locations: Phoenix VA Health Care System, Phoenix, AZ, Phoenix, Arizona
Conditions: Prediabetic State, Atherosclerosis, Metformin
International Non-selection Study for ERA® Test in Patients with Previous Implantation Failures
Recruiting
Women´s period comprises different hormonal stages, being one of them the stage for maximum receptivity and proper embryo implantation. This stage is named window of implantation (WOI), and is characterized by a specific molecular pattern than can be assessed by the Endometrial Receptivity Analysis (ERA® test), developed by Igenomix. Determining the WOI allows to schedule a personalized embryo transfer (pET) when the endometrium is most receptive for the implantation. The main objective of the... Read More
Gender:
FEMALE
Ages:
Between 18 years and 41 years
Trial Updated:
12/26/2024
Locations: Arizona Center for Fertility Studies, Phoenix, Arizona
Conditions: Infertility of Uterine Origin, Implantation Failure
Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At Home Measures
Recruiting
The goal of the study is to generate a biorepository of longitudinal biofluids-blood (plasma and serum), cerebral spinal fluid (CSF) and urine linked to genetics and longitudinal clinical information that are made available to the research community. To accomplish these goals, we will enroll 800 Amyotrophic Lateral Sclerosis (ALS) patients and 200 healthy controls from sites globally, over a 5 year time frame. Additionally, speech and motor function and spirometry measures will be collected bi-w... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/26/2024
Locations: Barrow Neurological Institute, Phoenix, Arizona
Conditions: Amyotrophic Lateral Sclerosis, Movement Disorders, Degenerative Disorder, Motor Neuron Disease
Understanding of Genetics by Men At Risk for Prostate Cancer
Recruiting
With this greater certainty regarding prognosis, men with localized prostate cancer are now equipped with make better treatment planning decisions. This study is designed to investigate the understanding of prognostic genetic technology in African American and rural White men at risk for localized prostate cancer.
Gender:
MALE
Ages:
Between 40 years and 95 years
Trial Updated:
12/24/2024
Locations: Mayo Clinic, Phoenix, Arizona
Conditions: Prostate Cancer
CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations
Recruiting
This phase II trial tests how well abiraterone acetate/niraparib (CJNJ-67652000 \[niraparib/abiraterone acetate fixed-dose combination\]) and prednisone works in treating patients with castration-resistant prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and who have a mutation in the SPOP gene. CJNJ-67652000 (niraparib/abiraterone acetate fixed-dose combination) is a drug which stops certain cancer cells from being able to repai... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
12/23/2024
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona
Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
Recruiting
This phase II trial evaluates lenvatinib for the treatment of hepatocellular carcinoma (HCC) that has come back (recurrent) after a liver transplant. HCC is a cancer of the liver and is the second leading cause of cancer-related deaths in the world. Liver transplantation is a potentially curative treatment option for HCC, however, up to 20% of patients develop recurrent disease after liver transplantation and prognosis remains poor. Lenvatinib may stop the growth of tumor cells by blocking some... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/23/2024
Locations: Mayo Clinic Arizona, Scottsdale, Arizona
Conditions: Recurrent Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
Transgenerational Metabolic-Immune Biomarkers of Neurological and Neurodevelopmental Disorders
Recruiting
The study involves up to 5 visits for a fasting blood draw, behavioral assessments, and/or questionnaires. Other samples may be collected when appropriate. This study is currently recruiting. There is no cost for visits or study-related exams.
Gender:
ALL
Ages:
18 years and below
Trial Updated:
12/23/2024
Locations: Southwestern Research and Resource Center, Phoenix, Arizona
Conditions: Autism Spectrum Disorder, Mitochondrial Pathology, Epilepsy, Brain Tumor, Psychiatric Disorder, Mitochondrial Diseases